Association of serum angiopoietin‑1, angiopoietin‑2 and angiopoietin‑2 to angiopoietin‑1 ratio with heart failure in patients with acute myocardial infarction

Chen,Shaomin; Guo,Lijun; Chen,Baoxia; Sun,Lijie; Cui,Ming

doi:10.3892/etm.2013.893

Association of serum angiopoietin‑1, angiopoietin‑2 and angiopoietin‑2 to angiopoietin‑1 ratio with heart failure in patients with acute myocardial infarction

Authors:
- Shaomin Chen
- Lijun Guo
- Baoxia Chen
- Lijie Sun
- Ming Cui
View Affiliations

Affiliations: Department of Cardiology, Peking University Third Hospital; Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing 100191, P.R. China
Published online on: January 14, 2013 https://doi.org/10.3892/etm.2013.893
Pages: 937-941

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association of the serum angiopoietin (Ang)‑1 and Ang‑2 levels and the Ang‑2 to Ang‑1 ratio (Ang‑2/Ang‑1) with heart failure (HF) in patients with acute myocardial infarction (AMI) during hospitalization. The serum Ang‑1 and Ang‑2 levels of the AMI patients were measured at admission to hospital. The correlations between serum Ang‑1, Ang‑2 and Ang‑2/Ang‑1 with HF were examined. Among 103 patients, 20 developed HF during hospitalization. The serum Ang‑2 level and Ang‑2/Ang‑1 were found to be significantly higher in the patients with HF than in the patients without HF (2,203.1±122.0 vs. 2,102.3±114.4 pg/ml, P=0.001 and 11.4±1.6x10‑2 vs. 10.6±1.1x10‑2, P=0.007, respectively). Serum Ang‑2 level and Ang‑2/Ang‑1 were negatively correlated with left ventricular ejection fraction (LVEF; r=‑0.352, P<0.001 and r=‑0.365, P<0.001, respectively) and positively correlated with the natural logarithm of the level of N‑terminal pro‑B‑type natriuretic peptide (LnNT‑proBNP, r=0.367, P<0.001 and r=0.304, P=0.003, respectively) and peak cardiac troponin T (cTnT, r=0.421, P<0.001 and r=0.278, P=0.009, respectively). However, the serum Ang‑1 level was not found to correlate significantly with LVEF (r=0.194, P=0.05), LnNT‑proBNP (r=‑0.116, P=0.266) or peak cTnT (r=‑0.056, P=0.607). In multivariable logistic regression analysis, Ang‑2 (P=0.031), Ang‑2/Ang‑1 (P=0.018) and NT‑proBNP (P=0.001) were revealed to be independently associated with HF. The present study reveals that Ang‑2 levels and Ang‑2/Ang‑1 are independent predictors of HF in AMI patients during hospitalization.

View Figures

View References

1.	Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, et al: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 33:2569–2619. 2012. View Article : Google Scholar : PubMed/NCBI
2.	Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 87:1161–1169. 1996. View Article : Google Scholar : PubMed/NCBI
3.	Thomas M and Augustin HG: The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 12:125–137. 2009. View Article : Google Scholar
4.	Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
5.	Post S, Peeters W, Busser E, et al: Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res. 45:244–250. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Patel JV, Lim HS, Varughese GI, Hughes EA and Lip GY: Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med. 40:215–222. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Iribarren C, Phelps BH, Darbinian JA, et al: Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study. BMC Cardiovasc Disord. 11:312011. View Article : Google Scholar
8.	Chen J, Yu H, Sun K, et al: Promoter variant of angiopoietin-2 and plasma angiopoietin-2 are associated with risk of stroke recurrence in lacunar infarct patients. Biochem Biophys Res Commun. 398:212–216. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Chen S, Guo L, Cui M, Sun L and Mi L: Dynamic changes in serum angiopoietin-1, angiopoietin-2 and angiopoietin-2/angiopoietin-1 ratio in acute myocardial infarction patients treated with primary percutaneous coronary intervention. Biomarkers. 17:441–446. 2012. View Article : Google Scholar
10.	Lee KW, Lip GY and Blann AD: Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 110:2355–2360. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Nadar SK, Blann A, Beevers DG and Lip GY: Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med. 258:336–343. 2005.
12.	Findley CM, Mitchell RG, Duscha BD, Annex BH and Kontos CD: Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol. 52:387–393. 2008. View Article : Google Scholar
13.	Lim HS, Blann AD, Chong AY, Freestone B and Lip GY: Plasma vascular endothelial growth factor, angiopoietin-1 and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care. 27:2918–2924. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Di Stefano R, Felice F and Balbarini A: Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des. 15:1095–1106. 2009.PubMed/NCBI
15.	Dallabrida SM, Ismail N, Oberle JR, Himes BE and Rupnick MA: Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res. 96:e8–e24. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Jeansson M, Gawlik A, Anderson G, et al: Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 121:2278–2289. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Chong AY, Caine GJ, Freestone B, Blann AD and Lip GY: Plasma angiopoietin-1, angiopoietin-2 and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol. 43:423–438. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Eleuteri E, Di Stefano A, Tarro Genta F, et al: Stepwise increase of angiopoietin-2 serum levels is related to haemodynamic and functional impairment in stable chronic heart failure. Eur J Cardiovasc Prev Rehabil. 18:607–614. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Buchner S, Debl K, Barlage S, et al: Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome. Clin Chem Lab Med. 48:875–881. 2010. View Article : Google Scholar
20.	Ricciuto DR, dos Santos CC, Hawkes M, et al: Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med. 39:702–710. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Ong T, McClintock DE, Kallet RH, Ware LB, Matthay MA and Liu KD: Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med. 38:1845–1851. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Turer AT and Hill JA: Pathogenesis of myocardial ischemia-reper-fusion injury and rationale for therapy. Am J Cardiol. 106:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
23.	van der Heijden M, van Nieuw Amerongen GP, van Bezu J, Paul MA, Groeneveld AB and van Hinsbergh VW: Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. PLoS One. 6:e234482011.PubMed/NCBI
24.	Fiedler U, Reiss Y, Scharpfenecker M, et al: Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 12:235–239. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Gu H, Cui M, Bai Y, et al: Angiopoietin-1/Tie2 signaling pathway inhibits lipopolysaccharide-induced activation of RAW264.7 macrophage cells. Biochem Biophys Res Commun. 392:178–182. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Tuo QH, Zeng H, Stinnett A, et al: Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol. 294:2547–2557. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Lee SW, Won JY, Lee HY, et al: Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade. Mol Med. 17:1095–1106. 2011.PubMed/NCBI